NewsHims & Hers Q3 2026: Revenue Rises, Profit Outlook Falls
The telehealth company's third-quarter sales grew rapidly, but higher costs and a narrower annual forecast complicate the picture for customers and investors.
This is a source-linked desk explainer, not first-hand reporting. Research and drafting may use AI-assisted tools. Follow the cited source links and read our editorial and corrections policy.
Source-linked desk analysis, not first-hand reporting. Research and drafting may use AI assistance; see our editorial policy.
Representative licensed financial-paperwork photograph; not a photograph of the company or earnings call. Photo: Leeloo The First / Pexels.
What did Hims & Hers report for Q3 2026?
The results show a business growing in sales and subscribers while spending more to support its product mix and international expansion. Revenue rose 49% compared with the third quarter of 2025. Subscriber count increased 13% to nearly 2.8 million, but the company reported a net loss rather than the $15.8 million profit recorded a year earlier.
Gross margin declined to 57% from 74% in the year-earlier quarter. This is important because sales growth alone does not show how much the company retains after direct costs. The company also reported adjusted EBITDA of $82.4 million, up from $78.4 million; adjusted EBITDA is a non-GAAP metric and is not the same as net income.
How did the 2026 revenue and profit outlook change?
| Metric | New forecast |
|---|---|
| Full-year 2026 revenue | $3.13B–$3.15B |
| Full-year adjusted EBITDA | $257M–$277M |
| Q4 2026 revenue | $875M–$895M |
The narrowed revenue range should not be confused with an upgrade to profit expectations: the company reduced its adjusted EBITDA outlook. The difference matters to anyone evaluating the sustainability of rapid expansion. The forecasts are forward-looking statements and may change.
What does the planned peptide offering mean?
Reuters reported that the company plans to offer certain peptide treatments, including NAD+, sermorelin and glutathione, in November, with other products potentially manufactured later. Crucially, regulatory enforcement discretion for some compounded substances does not mean FDA approval of a treatment for safety or effectiveness. Availability and legality can depend on the specific substance, preparation and circumstances.
Readers should not interpret a product launch as evidence of proven medical benefit. People considering a treatment should consult a qualified clinician about evidence, risks and alternatives, and check the FDA's current status for the exact product. The company's expectation that peptide sales will be immaterial in 2026 is not a forecast of proven medical outcomes.
What should U.S. customers and investors watch next?
Customers should distinguish FDA-approved branded medicines from compounded products and ask which exact product they would receive, who prescribes it and what monitoring is offered. Investors should watch the fourth-quarter results, the mix of U.S. and international revenue, subscriber retention and gross margins—not only headline revenue growth.
For related business context, read our Take-Two quarterly earnings breakdown and SoftBank earnings and investment analysis. These cover different companies and are linked only for readers comparing how earnings guidance differs from headline sales.
Sources and limitations
Hims & Hers November 9, 2026 results filed with the SEC (primary financial figures); Reuters coverage (independent reporting and peptide context); company investor-relations page (official releases). No treatment outcome, price or FDA approval is implied by this earnings report.